Literature DB >> 15113046

Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid.

Aejaz Nasir1, Edison Catalano, Stephanie Calafati, Alan Cantor, Hans E Kaiser, Domenico Coppola.   

Abstract

The distinction between follicular adenoma (FAD) and follicular carcinoma (FCA) of the thyroid can be particularly challenging in routine practice of diagnostic surgical pathology. It often requires examination of several histologic sections in order to identify the presence of unequivocal capsular and/or vascular invasion. To investigate the role of immunohistochemical markers in the differential diagnosis of follicular lesions of the thyroid, we studied the pattern of expression of p53, Bcl-2 and of the adhesion molecules CD44V6 and CD57, in 20 FADs and 21 FCAs of the thyroid. Ninety percent of FCAs exhibited strong nuclear p53 expression. p53 stain was seen in only 15% of FADs (p<0.0001), and it was weak. Bcl-2 cytoplasmic immunoreactivity was observed in 57% of FCAs and 60% of FADs (p=1.00). Similarly, membranous CD44V6 staining was seen in 81% of FCAs, but in only 20% of FADs (p=0.0001). CD57 was present in the cytoplasm of 71% of FCAs and 15% of FADs (p=0.0004). None of the markers studied correlated with tumor size. The results of this study indicate that immunohistochemical detection of p53, CD44V6 and CD57 may have practical utility in the differential diagnosis of FCAs from FADs in routine surgical pathology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15113046

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  4 in total

Review 1.  The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.

Authors:  Marc-André Fortin; Alexei V Salnikov; Marika Nestor; Nils-Erik Heldin; Kristofer Rubin; Hans Lundqvist
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-03       Impact factor: 9.236

3.  Can CD10 be used as a diagnostic marker in thyroid pathology?

Authors:  Gülçin Yegen; Mehmet Akif Demir; Yeşim Ertan; Olcay Ak Nalbant; Müge Tunçyürek
Journal:  Virchows Arch       Date:  2008-11-25       Impact factor: 4.064

Review 4.  Immunohistochemical Biomarkers in Thyroid Pathology.

Authors:  Zubair Baloch; Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.